The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this B1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the efficacy of radioiodine treatment.
Introduction
Thyroid cancer is the most common endocrine malignancy, and radioiodine ( 131 I) is the primary adjunctive treatment for patients with differentiated thyroid cancer.
Some mammalian cells, most notably thyroid follicular cells, take up iodide, organify it and incorporate it into proteins. In 1996, the gene encoding the molecule responsible for iodide transport, the human sodium iodide symporter (NIS), was cloned (Dai et al., 1996; Smanik et al., 1996) . The ability of malignant thyroid cells to actively transport iodide via NIS function provides a unique and effective delivery system for detection and destruction of these cells with therapeutic doses of radioiodine. Unfortunately, however, NIS expression and function are generally reduced in differentiated thyroid cancers compared with normal thyroid tissue. Understanding of the factors repressing NIS activity in thyroid tumours is thus important in improving 131 I delivery to those tumours that fail to uptake radioiodine effectively.
Numerous factors have been shown to influence NIS activity in vitro, including thyrotropin (TSH), dexamethazone and all-trans retinoic acid (Kogai et al., 1997 (Kogai et al., , 2000 Spitzweg et al., 1999) . One previous study in rat thyroid FRTL-5 cells implicated the pituitary tumor transforming gene (PTTG) in the downregulation of the NIS . More recently, an association between PTTG overexpression and decreased radioiodine uptake during follow-up has been reported (Saez et al., 2006) . PTTG stimulates expression of basic fibroblast growth factor (FGF-2) (Zhang et al., 1999b; Ishikawa et al., 2001) and vascular endothelial growth factor (VEGF) (McCabe et al., 2002) , and has been implicated in the pathogenesis of numerous neoplastic conditions (see McCabe, 2001; Yu and Melmed, 2001) . PTTG is a multifunctional human securin, with a role in the control of mitosis (Zou et al., 1999; Yu et al., 2000; Zur and Brandeis, 2001) , cell transformation (Pei and Melmed, 1997; Zhang et al., 1999b) , DNA repair (Romero et al., 2001) , gene regulation (Zhang et al., 1999b; Pei, 2000; McCabe et al., 2002) and fetal development (Boelaert et al., 2003b) . PTTG overexpression has been reported in tumours of the thyroid , pituitary (Zhang et al., 1999a; McCabe et al., 2003) , colon (Heaney et al., 2000) , ovary (Puri et al., 2001) and breast (Puri et al., 2001) , as well as in haematopoietic neoplasms (Dominguez et al., 1998) . In thyroid, pituitary, oesophageal and colorectal tumours, high PTTG expression correlates with poor prognosis (Zhang et al., 1999a; Heaney et al., 2000; Shibata et al., 2002; Boelaert et al., 2003a; McCabe et al., 2003) . We and others have previously demonstrated aberrant expression of FGF-2 and its receptor in thyroid cancer (Eggo et al., 1995) , and we have reported a significant association between PTTG expression in the primary thyroid tumour and recurrence of that tumour during early follow-up (Boelaert et al., 2003a) . In addition, our studies revealed that FGF-2 overexpression in thyroid cancers was significantly associated with lymph node invasion and distant metastasis at presentation (Boelaert et al., 2003a) .
The mechanism by which PTTG regulates FGF-2 was clarified through the isolation of PTTG-binding factor (PBF) (Chien and Pei, 2000) . PBF is a 22-kDa protein, also known as c21orf3 (Yaspo et al., 1998) , that exhibits nuclear and cytoplasmic expression in a manner similar to PTTG. PBF possesses a C-terminus nuclear localization signal, ablation of which prevents PTTG regulation of FGF-2 (Chien and Pei, 2000) . We characterized PBF expression in thyroid tumours, and demonstrated it to be a transforming gene in vitro, and to be tumorigenic in vivo .
Given that PTTG and PBF are upregulated in thyroid cancer (Boelaert et al., 2003a; Stratford et al., 2005; Saez et al., 2006) and stimulate FGF-2 expression (Zhang et al., 1999b) , which has been shown to repress iodide uptake (Cocks et al., 2003) , and that PTTG is associated with reduced iodide uptake in vivo (Saez et al., 2006) , we assessed whether PTTG and PBF might have a direct role in the repression of NIS expression and function previously reported in thyroid tumours. Our results show that PTTG and PBF inhibit NIS messenger RNA (mRNA) expression and iodide uptake in vitro. Further, we have identified a critical promoter site at which PTTG and PBF mediate their repression of the NIS gene in human and rat thyroid cells. We therefore propose that the levels of expression of PTTG and PBF in papillary and follicular thyroid tumours may directly affect the treatment outcome following radioiodine therapy.
Results

NIS expression is reduced in thyroid cancer
We assessed NIS mRNA and protein expression in our cohort of normal and malignant thyroid samples. Details of patients with a diagnosis of thyroid cancer are given in Table 1 . NIS mRNA was significantly reduced in thyroid cancers (47% reduction, n ¼ 27, P ¼ 0.005) compared with normal thyroid (n ¼ 11). Further, NIS mRNA was lower in cancers displaying recurrence early during follow-up (n ¼ 6) than in nonrecurrent cancers (n ¼ 18, P ¼ 0.02), as well as in nodepositive (n ¼ 9) compared with node-negative tumours (n ¼ 15, P ¼ 0.03) (Figure 1a) . Taking into account known prognostic indicators of age, gender, tumour size and tumour type, NIS expression was independently associated with early recurrence (R 2 ¼ 0.47, P ¼ 0.03) and nodal involvement (R 2 ¼ 0.67, Po0.001). Female  Pap  2  0  0  0  61  2  o40  Male  Pap  2  1a  0  1  52  3  o40  Female  Pap  2  0  0  0  18  4  o40  Male  Pap  3  1b  1  0  22  5  >40  Female  Foll  4  0  0  1  27  6  >40  Female  Pap  3  1a  0  0  34  7  >40  Male  Pap  1  0  0  0  15  8  >40  Female  Foll  3  0  0  0  48  9  >40  Female  Foll  3  0  0  0  24  10  >40  Female  Foll  3  0  0  0  29  11  >40  Female  Pap  x  1b  1  1  27  12  o40  Female  Pap  3  1b  0  0  8  13  >40  Female  Pap  1  0  0  0  64  14  o40  Female  Pap  3  0  0  0  68  15  o40  Female  Foll  2  0  0  1  56  16  >40  Male  Pap  2  1b  1  1  63  17  >40  Male  Pap  3  1b  0  0  58  18  o40  Female  Pap  1  0  0  0  7  19  >40  Female  Foll  2  0  0  0  6  20  >40  Female  Pap  2  0  0  0  9  21  >40  Female  Pap  1  0  0  1  28  22  o40  Male  Pap  1  1b  1  0  12  23  >40  Female  Foll  3  0  0  0  8  24  >40  Male  Pap  3  1b  1  0  5 Abbreviations: foll, follicular; FU, follow-up; Pap, papillary. These details were available for 24 patients from the group of 27 cancer specimens studied. Demographic details (age, sex), carcinoma type (pap; foll), TNM a staging, recurrence status (R) and FU period in months are displayed for each patient a T:X primary tumour size cannot be assessed. (1), intrathyroidal tumour p1 cm in greatest dimension; (2), intrathyroidal tumour >1-4 cm in greatest dimension; (3), intrathyroidal tumour >4 cm in greatest dimension; (4), tumour of any size, extending beyond thyroid capsule. N0, no nodes involved; (1a), ipsilateral cervical nodes involved; (1b), bilateral, midline or contralateral cervical nodes or mediastinal nodes. M0, no distant metastases; (1), distant metastases.
Western blotting in a subset of samples confirmed our finding of reduced NIS mRNA expression in differentiated thyroid tumours compared with normal thyroid. Scanning densitometry (Figure 1b ) indicated that the reduction in NIS protein expression was statistically significant (normal ¼ 0.3770.06, tumour ¼ 0.2170.02 scanning densitometry units; Po0.05). Further, immunohistochemical assessment, although not formally quantified, showed NIS protein expression to be reduced in papillary and follicular tumour samples compared with normal ( Figure 1c) . Thus, in common with several previous reports (Liou et al., 2000; Arturi et al., 2001; Ringel et al., 2001) , NIS expression is reduced in our samples of differentiated thyroid cancer compared with normal thyroid tissue.
PTTG and PBF downregulate NIS expression and iodide uptake in vitro We and others have previously demonstrated that thyroid cancers show increased expression of PTTG Boelaert et al., 2003a; Saez et al., 2006) , and we recently reported that PBF is also overexpressed in differentiated thyroid tumours compared with normal tissue . In addition, two reports have indicated that PTTG represses NIS and that PTTG protein expression is negatively correlated with radioiodine uptake in thyroid tumours (Saez et al., 2006) . We therefore investigated whether PTTG and PBF can repress NIS expression and iodide uptake in primary thyroid cells in vitro. Transient transfection of a full-length PBF cDNA in primary human thyrocytes resulted in a 95% inhibition of NIS mRNA (n ¼ 6, Po0.001, compared with vectoronly control (VO)) (Figure 2a) . Similarly, when we investigated PBF's binding partner PTTG, PTTG overexpression also significantly reduced NIS mRNA expression (86% reduction vs VO, n ¼ 15, Po0.001). Co-transfection of PTTG and PBF resulted in an enhanced repression compared to PTTG alone (PBF/ PTTG: 96% inhibition, n ¼ 6, Po0.001 compared with VO; P ¼ 0.05 PBF/PTTG compared with PTTG). A mutant of PTTG (SH3-), which is unable to transactivate FGF-2 (Boelaert et al., 2004) , also repressed NIS mRNA, albeit to a slightly lower degree than wild type (WT) (81% compared with VO, n ¼ 6, Po0.01) (Figure 2a ).
To assess whether PTTG and PBF's influence on NIS mRNA was associated with changes at the functional level, NIS activity was assessed through measurement of 125 I uptake in parallel experiments (Figure 2b ). PTTG and PBF both repressed 125 I uptake (PTTG -59% reduction vs VO, n ¼ 6, Po0.001; PBF -68% reduction vs VO, n ¼ 6, Po0.001). Co-transfection of PTTG and its interacting factor PBF resulted in a synergistic inhibition of NIS activity compared with either gene alone (PTTG/PBF -83% reduction compared with VO, n ¼ 6, Po0.001; 46% reduction compared with PBF, Po0.05; 59% reduction compared with PTTG, Po0.05). In common with the mRNA data, SH3-PTTG demonstrated a reduced ability to repress NIS compared with WT PTTG (SH3 34% inhibition, WT 59% inhibition, n ¼ 6, Po0.01). 
PTTG, but not PBF, represses NIS via FGF-2
Given that PTTG and PBF both repress NIS, and that the SH3 mutant of PTTG was less effective than WT, we investigated whether NIS repression is mediated via FGF-2 in thyroid cells. Enzyme-linked immunosorbent assay (ELISA) (Figure 3a ) demonstrated that transfection of PTTG increased FGF-2 secretion in primary thyrocytes roughly 1.4-fold after 48 h (immunoglobulin (Ig) control ¼ 35.071.6 pg/ml secreted FGF-2, WT PTTG ¼ 49.272.4 pg/ml FGF-2, n ¼ 8, Po0.001), and that this could be reduced to basal levels by the addition of an anti-FGF-2 antibody (Ab) (PTTG þ Ab ¼ 33.771.3 pg/ml secreted FGF-2). Using this approach to disrupt FGF-2 signalling, we investigated the influence of PTTG and PBF on Taken together, these data suggest that PTTG repression of NIS is influenced by FGF-2 secretion in thyrocytes, whereas PBF downregulation of NIS is not affected by FGF-2 secretion.
PTTG and PBF repression via the human NIS promoter
To examine repression of NIS via its promoter, we next performed a series of experiments in rat thyroid FRTL-5 cells, which represent a homogeneous and well-characterized thyroid line in which to study NIS promoter I uptake, but anti-FGF-2 antibody treatment did not alter this (n ¼ 12, P ¼ NS). Transfection of WT PTTG resulted in a reduction in 125 I uptake, which could be significantly abrogated by FGF-2 Ab treatment (n ¼ 12, Po0.001). Co-transfection of PTTG and PBF repressed NIS activity, although this was only minimally affected by depletion of secreted FGF-2 (n ¼ 12, P ¼ 0.06; Po0.001 compared with VO).
activity. We employed a number of pGL3-luc promoter constructs previously used in NIS studies (Figure 4a ; Taki et al., 2002) . These included 544 bp of the proximal NIS promoter (basal-NIS), the human NIS upstream enhancer element (hNUE), and a fusion of the two (hNUE-basal NIS). The proximal 544 bp of the NIS promoter contains the transcription initiation site and has been shown to mediate basal NIS activity (Behr et al., 1998; Ryu et al., 1998) , whereas hNUE confers thyroid-specific and TSH-cAMP responsive transcriptional activity (Schmitt et al., 2001; Taki et al., 2002) .
To determine whether PTTG can repress the NIS promoter via the proximal 544 bp, or else via the upstream enhancer, we co-transfected reporter constructs and PTTG into FRTL-5 cells and examined luciferase activity. Compared to VO controls, PTTG was unable to repress the basal promoter, but significantly reduced activity of the hNUE element (4577% reduction, Po0.001, n ¼ 9; VO promoter activity taken as 100% throughout) (Figure 4b) . A reporter construct containing both elements was also repressed by PTTG (1973% reduction, Po0.001, n ¼ 9). (a) pGL3 plasmid constructs used in the study of NIS regulation (not to scale). The transcription initiation site is at À375 within the 544 bp basal-NIS construct. hNUE-SV40 contained 1149 bp of the NIS promoter, between bases À9847 and À8968, within which lies the 296 bp hNUE, driven by SV40. hNUE-basal NIS comprised the basal 544 bp downstream of hNUE. The pGL3 SV40 construct was used as control. All plasmid constructs were as published previously (Taki et al., 2002) . (b) VO and PTTG transfection of FRTL-5 cells co-transfected with basal-NIS, hNUE-SV40 and hNUE-basal NIS. Luciferase activity was corrected for Renilla expression, and was expressed relative to VO ( ¼ 1.0). ***Po0.001. (c) The influence of PBF overexpression on NIS promoter activity, relative to VO. ***Po0.001.
In separate experiments, we examined the influence of PBF on the same NIS elements. In contrast to PTTG, PBF significantly repressed both the basal promoter (2874% repression, Po0.001, n ¼ 9) and hNUE (5974%, Po0.001, n ¼ 9) compared to VO, and when both elements were combined, still elicited significant repression (2275%, Po0.001, n ¼ 9).
Taken together, these experiments show that PTTG and PBF are able to repress specific regions of the human NIS promoter.
The PAX8/USF1 site is critical to PTTG and PBF action Next, we examined the hNUE element in detail, searching for standard promoter elements that might help us understand in more detail how PTTG and PBF exert their effects on the human NIS promoter. Between bases À9286 and À9298 of hNUE lies a previously characterized PAX8 site, which has been reported to mediate basal NIS expression (Taki et al., 2002) . Interestingly, Lin et al. (2004) previously noted that a complexed upstream stimulating factor 1 (USF1) domain lies within the PAX8 consensus (Figure 5a ), and that this is conserved in rat, mouse and human NIS genes. Three genes that show transcriptional regulation by PTTG -FGF-2 (Zhang et al., 1999b) , VEGF (McCabe et al., 2002) and ID3 (Kim et al., 2006) -also harbour USF1 sites (unpublished observations), and USF1 has been shown to be critical to PTTG regulation of c-myc (Pei, 2001) . Therefore, we considered that this region of hNUE might confer PTTG's transcriptional regulation of NIS.
We created two mutants, one abrogating the USF1 consensus sequence, but retaining the PAX8 site (USF1 mutant), and one removing the PAX8 consensus but retaining USF1 (PAX8 mutant) (see Figure 5a) . We then performed initial experiments to examine the influence of mutation on the basal activity of WT and mutated hNUE. As expected, compared with empty vector (pGL3), the simian virus (SV)40 construct expressed significant luciferase activity (14.771.8-fold induction vs pGL3; Figure 5b ), and addition of the hNUE sequence augmented this effect (44.873.5-fold vs pGL3, n ¼ 9, Po0.001; 3.070.4-fold vs pGL3-SV40, n ¼ 9, Po0.001). Although both mutants resulted in a significant disruption of promoter activity compared to hNUE-SV40, they retained greater activity than the SV40 construct alone, that is, both mutants showed partial inactivation of the hNUE element (Figure 5b ).
To determine whether PTTG and PBF were still able to repress the hNUE element in the face of disrupted USF1 and PAX8 sites, we co-transfected FRTL-5 cells with WT and mutated promoter constructs, as well as with VO, PTTG, SH3 PTTG and PBF. Again, WT PTTG repressed promoter activity via hNUE (5175% reduction, n ¼ 9, Po0.001) (Figure 5c ). In contrast, the SH3 mutant lost the ability to repress at the hNUE site, and in fact yielded an augmentation of promoter activity (4875% increase, n ¼ 9, Po0.001). Interestingly, substitution of two bases within the USF1 consensus abrogated the ability of PTTG to inhibit NIS activity (VO ¼ 100%, PTTG ¼ 106725%, n ¼ 9, P ¼ NS). SH3 data were consistent with those for WT hNUE-SV40. Disruption of PAX8 in the presence of WT USF1 failed to significantly diminish PTTG's ability to repress the hNUE-SV40 element (55710% repression, n ¼ 9, Po0.001). Again, the SH3 mutant was unable to repress the PAX8-mutated hNUE sequence, and showed no difference from VO control.
In parallel experiments, we determined the influence of the same mutations on PBF repression of hNUE. Again, PBF inhibited hNUE activity (5074% repression, n ¼ 9, Po0.001; Figure 5d ), and this was abrogated by mutation of the USF1 site (VO ¼ 100%, USF1 ¼ 5712% inhibition, n ¼ 9, P ¼ NS). Of note, deletion of the PAX8 site also prevented PBF repression of the hNUE element, and in fact resulted in an upregulation of hNUE activity (VO ¼ 100%, PAX8 ¼ 155728%, n ¼ 9, Po0.05).
Overall, our data suggest that the USF1/PAX8 site plays a critical role in mediating the repression of PTTG and PBF on the human NIS promoter. PBF requires integrity of both USF1 and PAX8, whereas PTTG signals via the USF1 site.
PTTG and PBF repression of NIS in human thyroid cells
Having examined NIS promoter regulation in rat thyroid cells, we returned to primary human thyroid cell cultures to investigate whether PTTG and PBF could repress the NIS promoter in human cells (Figure 6 ). Data were broadly in agreement with the FRTL-5 findings, although PBF did not repress the basal promoter (VO ¼ 100%, PBF ¼ 102713%, n ¼ 9, P ¼ NS). However, hNUE, the critical response element for PTTG and PBF regulation of NIS, remained strongly repressed by both genes (PTTG: 46713% inhibition, n ¼ 9, P ¼ 0.004; PBF: 4579% inhibition, n ¼ 9, Po0.001).
Taken together, these data suggest that PTTG and PBF repress NIS mRNA expression and iodide uptake, and that, in rat and human thyroid cells, the critical region of the NIS promoter is the hNUE enhancer element.
Discussion
NIS is an integral membrane glycoprotein which mediates active iodide (I À ) transport into thyroid cells, as the crucial first step in thyroid hormone biosynthesis (see Boelaert and Franklyn, 2003; Dohan et al., 2003) . The ability of the thyroid to accumulate iodide has provided an effective means for therapeutic doses of radioiodine to target and destroy iodide-transporting differentiated thyroid cancers and their metastases. However, most thyroid tumours exhibit reduced iodide uptake, although mRNA (Smanik et al., 1997; Lazar et al., 1999; Ryu et al., 1999; Arturi et al., 2000; Park et al., 2000; Tanaka et al., 2000) and protein (Caillou et al., 1998; Jhiang et al., 1998; Saito et al., 1998; Castro et al., 1999) studies have demonstrated inconsistent findings regarding reduction of NIS expression in thyroid cancer per se.
In our series of papillary and follicular tumours, NIS mRNA expression showed a mean reduction of approximately 50% compared with normal thyroid samples. We noted that, taking into account known prognostic indicators of age, gender, tumour size and tumour type, low NIS mRNA expression was independently associated with nodal involvement at diagnosis and early recurrence. In addition, Western blotting and immunohistochemical analyses supported the mRNA findings of reduced NIS expression in thyroid tumours.
Our observation of reduced NIS mRNA expression in thyroid tumours (especially those demonstrating adverse behaviour) is consistent with reduced NIS function in follicular and papillary tumours. Several potential mechanisms for this have been proposed. Recently, PTTG has been shown to repress iodide uptake in rat thyroid cells , and to inversely correlate with decreased radioiodine uptake during follow-up (Saez et al., 2006) . We therefore investigated whether PTTG and its binding factor PBF were able to repress the expression and function of the NIS gene in vitro.
Both PTTG and PBF significantly downregulated NIS mRNA expression and iodide uptake in primary cultures of human thyroid cells. Furthermore, when cotransfected, a synergistic effect was apparent, in that mutual repression was greater than with PBF or PTTG alone. The SH3 mutant of PTTG, which is unable to upregulate FGF-2 (Boelaert et al., 2004) , showed enhanced iodide uptake compared with WT PTTG, suggesting that PTTG repression of NIS activity is at least partially dependent on FGF-2. This was confirmed by depletion of FGF-2 in cell media using an anti-FGF-2 antibody, which resulted in reduced NIS downregulation. An alternative pathway is also likely to exist, given that PBF also inhibited NIS expression and PTTG and PBF were unable to repress the basal NIS promoter, but both inhibited hNUE activity. **Po0.01; ***Po0.001.
activity, despite being unable to stimulate FGF-2 expression . To this end, we examined the transcriptional regulation of NIS at its promoter, in a discrete set of experiments in rat thyroid FRTL-5 cells. Employing a series of constructs used in previous NIS promoter studies (Taki et al., 2002) , we examined the influence of PTTG and PBF on two critical regions. The first encompassed 544 bp, the basal NIS promoter, which contains the transcription initiation site, has been shown to mediate basal NIS activity (Behr et al., 1998; Ryu et al., 1998) . The second 1149-bp fragment included the 296 bp hNUE, which confers thyroid-specific and TSH-cAMP responsive transcriptional activity (Schmitt et al., 2001; Taki et al., 2002) , and contains a PAX8 binding site and a CRE-like sequence. These separate and critical regions of the human NIS promoter were regulated in subtly different manners by PTTG and PBF.
The basal NIS promoter was repressed by PBF, but not by PTTG. Both genes inhibited promoter activity most strongly via the hNUE element, however. To narrow down the potential region of hNUE essential for PTTG and PBF regulation, we focused upon a previously characterized PAX8 site, which has been reported to mediate basal NIS expression (Taki et al., 2002) . Of note, the PAX8 consensus harbours an internal and evolutionarily conserved USF1 site (Lin et al., 2004) . USF1 sites are present in the promoters of FGF-2, VEGF and ID3 -genes all regulated by PTTGand USF1 has been shown to be critical to PTTG regulation of c-myc (Pei, 2001) . Therefore, we considered the hypothesis that this region of hNUE is necessary for PTTG's transcriptional regulation of NIS.
The basal activity of the hNUE element was reduced both by USF1 and PAX8 mutations, but retained activity above that of the control pGL3-SV40 vector. When we abrogated the USF1 site, but kept PAX8 intact, PTTG lost the ability to repress hNUE. PAX8 deletion failed to influence PTTG's action. Conversely, PBF required integrity of both the USF1 and PAX8 consensus sequences in order to inhibit hNUE activity. The use of the SH3 mutant of PTTG provided intriguing data. SH3-PTTG was able to repress NIS mRNA expression and iodide uptake, although to a lesser degree than WT PTTG. When we examined its influence on WT and mutated hNUE constructs, it was apparent that abrogation of the SH3-binding domain rendered PTTG unable to repress at hNUE. As SH3-retains the ability to regulate NIS mRNA expression (Figure 2a) , it is likely that its effect is mediated via NIS promoter region(s) other than the relatively small hNUE element examined here. Interestingly, the SH3-PTTG actually induced promoter activity of the native hNUE construct and the USF-1 mutant. We hypothesize that this reflects interference with the endogenous repression of NIS mediated by WT PTTG expression in FRTL5 cells, although this would need to be tested in different experimental systems.
Overall, the findings of the current work shed light on the differential mechanisms of action of PTTG and PBF in the repression of NIS promoter activity and iodide uptake. In a further set of investigations, we are now investigating whether PTTG and PBF bind directly at the hNUE site to mediate their effects, and whether this binding is prevented by subtle mutations of USF1 and PAX8. Our hypothesis, based on our current understanding, is that PTTG and PBF repress NIS by interfering with the binding of the two transcriptional regulators PAX8 and USF1 to the NIS promoter, and that PTTG and PBF show different affinities of binding at the USF1/PAX8 consensus. However, the data arising from the current investigation suggest that the USF1/PAX8 site of the hNUE confers alternative regulation of NIS expression by two genes not previously predicted to interact directly at this site.
An alternative element of the hNUE, which we did not consider in the current investigation, is the CRE-like site between bases À9244 and À9250 of the human NIS gene, approximately 50 bp downstream of the PAX8 consensus. This degenerate CRE motif has been reported along with the PAX8 site as being necessary for full hNUE activity (Taki et al., 2002) . The absence of a putative CRE binding protein in human papillary thyroid cancer cells was suggested to confer reduced NIS promoter activity compared with normal thyroid cells, which expressed the as yet unidentified protein abundantly (Taki et al., 2002) . Subsequently, numerous proteins have been demonstrated to bind at this site, including both the Fos/Jun and CREB/ATF subfamilies of b-ZIP transcription factors (Chun et al., 2004) . These intriguing findings add an extra layer of complexity to the regulation of hNUE.
As our initial observations of PTTG and PBF repression of NIS expression and function were in primary thyroid cells, we finally examined whether hNUE was active in human cells. Both PTTG and PBF were able to significantly inhibit hNUE in a similar manner to their action observed in FRTL-5 cells, confirming that in human thyroid cells, hNUE is targeted by these two genes, which show upregulation in differentiated thyroid cancer Boelaert et al., 2003a; Stratford et al., 2005; Saez et al., 2006) .
The clinical relevance of PTTG and PBF repression of NIS activity relates to their likely influence upon the efficacy of 131 I therapy. The ability of the thyroid to accumulate I À provides the basis for radioiodine ablation of iodide-transporting differentiated thyroid cancers and their metastases. Taken together, we propose that by downregulating NIS, particularly at the USF1/PAX8 consensus of hNUE, increased PTTG and PBF fundamentally influence the prognosis of differentiated thyroid cancers, at least in part by affecting their sensitivity to ablative 131 I therapy.
Materials and methods
Thyroid samples and thyroid cell culture Collection of thyroid samples was in accord with approval of the Local Research Ethics Committee, and subjects gave informed written consent. None of the patients had been on radioiodine treatment. Findings from 27 tumour specimens were compared with those from 11 samples of histologically normal thyroid tissue obtained from patients undergoing laryngectomy for laryngeal cancer; no normal thyroid specimen had any histological evidence of tumour invasion or small occult primary thyroid tumours. Tissues were immediately snap frozen and stored at À801C.
Patients' demographic details and thyroid function pre-and postoperatively were recorded. The tumour node metastasis (TNM) staging of tumours at presentation, as well as early recurrence of the cancer during follow-up, were recorded. Recurrence was defined as evidence on imaging for recurrent disease in the thyroid bed or elsewhere or rising serum thyroglobulin in association with TSH suppression on thyroxine (T4) therapy. Subsequently, tumour recurrence was confirmed histologically in four out of six cases, and in the remaining two, by demonstrating regression of lesions on imaging and falling thyroglobulin after ablative radioiodine therapy.
Human thyroid follicular cells were prepared from surgical specimens as described previously (Eggo et al., 1996; Ramsden et al., 2001) . In brief, thyroid tissue was digested using 0.2% collagenase. Follicles were plated in medium described by Ambesi-Impiombato et al. (1980) , supplemented with TSH (300 mU/l), insulin (100 mg/l), penicillin (10 5 U/l), streptomycin (100 mg/l) and 2% newborn bovine calf serum. After 72 h, serum was omitted, and experiments were performed following 8-11 days of culture. FRTL-5 cells were grown in identical medium to primary thyroid cells, except with 5% fetal bovine serum.
Transient transfection and plasmids
Before transfection experiments, cells were washed in phosphate-buffered saline (PBS) (FRTL5s) or Hanks'balanced saline solution (HBSS) (for primary cultures). Cells were transfected in a 12-or 24-well plates using Fugene 6 reagent (Roche, Indianapolis, IN, USA), as per the manufacturer's instructions. WT and mutated PTTG and PBF plasmids were as described previously (Boelaert et al., 2004; Stratford et al., 2005) . For luciferase assays of NIS promoter activity, constructs were as described previously (Taki et al., 2002) . The QuickChange Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK) was used to disrupt the putative USF1 and PAX8 sites of the human NIS promoter hNUE element. Primers used were: USF1 -GCTGTCAAGCAGTTCTGCGT GAGTGCCCTGG; PAX8 -GGCTGTCAAGCAGGTCCA CGTGGTTCCCCTGGGGG. Underlined bases represent the actual nucleotide substitutions. Following transfection, cells were harvested in 0.5 ml tri reagent 48 h later, or in 250 ml of passive lysis buffer for luciferase assays. Control transfections utilized equal amounts of blank plasmid. Transfection efficiency in primary thyrocytes was determined through b-Gal staining, and ranged from 45 to 95%. In FRTL-5 experiments, transfection efficiency was gauged through Renilla expression. In either case, fold changes were adjusted in each experiment to reflect individual transfection efficiencies.
RNA extraction and reverse transcription Total RNA was extracted from primary thyroid cell cultures utilizing the Sigma Trisol kit -a single step acid guanidinium phenol-chloroform extraction procedure -following manufacturer's guidelines. RNA was reverse transcribed using avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison, WI, USA) in a total reaction volume of 20 ml, with 1 mg of total RNA, 30 pmol random hexamer primers, 4 ml of Â 5 AMV reverse transcriptase buffer, 2 ml of deoxynucleotide triphosphate (dNTP) mix (200 mM each), 20 U of ribonuclease inhibitor (Rnasin, Promega) and 15 U of AMV reverse transcriptase (Promega).
Quantitative PCR Expression of specific messenger RNAs was determined using the ABI PRISM 7700 Sequence Detection System. RT-PCR was carried out in 25 ml volumes on a 96-well plates, in a reaction buffer containing Â 1 TaqMan Universal PCR Master Mix, 175 nmol TaqMan probe and 900 nmol primers, as we have described previously (McCabe et al., 2002; Boelaert et al., 2003b; Kim et al., 2005 Kim et al., , 2006 . All reactions were multiplexed with a pre-optimized control probe for 18S ribosomal RNA (PE Biosystems, Warrington, UK). NIS primer and probe sequences were: forward primer: CCCCAG CTCAGGAATGGA; reverse primer: CGTAATAGAGATA GGAGATGGCATAGAA; probe: CCAGCCGGCCCGCCT TAGC.
Before the determination of NIS mRNA expression through TaqMan RT-PCR, validation experiments were carried out across a range of starting mRNA quantities (1-100 ng) to determine the linearity and efficiency of amplification, and to assess the independence of 18S rRNA and NIS amplification. Linear amplification was confirmed across the range of starting mRNA concentrations, and the gradients of NIS and 18S rRNA differed by less than 0.1, confirming their effective independence. As per the manufacturer's guidelines, data were expressed as cycle threshold (C t ) values, and used to determine DC t values (DC t ¼ C t of the target gene (NIS) minus C t of 18S rRNA). To exclude potential bias owing to averaging data which had been transformed through the equation 2
ÀDDCt to give fold changes in gene expression, all statistics were performed with DC t values, as we have described previously (Boelaert et al., 2003b; Kim et al., 2005) . The target gene probe was labelled with FAM, and the 18S rRNA probe with VIC. Reactions were as follows: 501C for 2 min, 951C for 10 min; then 40 cycles of 951C for 15 s and 601C for 1 min.
Western blotting
Whole cell protein extracts were prepared from thyroid tissues in lysis buffer (100 mM sodium chloride, 0.1% Triton X-100 and 50 mM Tris (pH 8.3)) containing enzyme inhibitors. Protein concentration before loading was measured by the Bradford assay with bovine serum albumin as standard. Western blot analyses were performed as we have described previously (McCabe et al., 2002; Boelaert et al., 2003a) . Briefly, soluble proteins (30 mg) were separated by electrophoresis in 12.5% sodium dodedecyl sulphate (SDS) polyacrylamide gels, transferred to polyvinylidene fluoride membranes, incubated in 5% non-fat milk in PBS with 0.1% Tween, and followed by incubation with a rabbit polyclonal NIS antibody (1:1500), kindly provided by Dr Nancy Carrasco (Albert Einstein College of Medicine, New York, USA). For scanning densitometric analysis, four tumours (two papillary and two follicular) and four normal thyroid samples were chosen at random, and run twice against b-actin expression (monoclonal anti-b-actin clone AC-15, used at 1:10 000; Sigma-Aldrich, Poole, UK). Subsequently, data were normalized to b-actin expression.
NIS immunohistochemistry
Formalin-fixed paraffin-embedded sections of representative normal and tumourous thyroid were immunostained using an avidin-biotin peroxidase technique (Vectastain Elite, Vector Laboratories, Peterborough, UK). All reagents were prepared as per the kit instructions. Briefly, after dewaxing and rehydration the sections were processed in 1 mg/ml hyaluronidase in 0.1 mol/l sodium citrate buffer (pH 5.5) for 30 s for antigen retrieval. Slides were then rinsed in washing buffer (TBS/0.3% Tween 20) and incubated with 0.03% hydrogen peroxide in TBS (pH 7.4) to block endogenous peroxidase activity. After washing in 0.02 M Tris/0.15 M NaCl (pH 7.4; TBS), the slides were overlain with 5% washing buffer for 30 min at room temperature, before incubation with a specific mouse monoclonal antibody to human NIS (1:1000; kindly provided by Dr J Morris, Mayo Clinic, Rochester, USA). For negative controls the primary antibody was replaced by nonimmune serum. After three 5 min washes in TBS, the sections were incubated with biotinylated secondary antibody for 30 min, followed, after further TBS washes, by addition of the avidin-biotin peroxidase complex. The reaction was developed by incubation in NovaRed (Vector Laboratories, Peterborough, UK) for 5-10 min. Sections were lightly counterstained with Mayers Haematoxylin, dehydrated, cleared and mounted in synthetic resin.
Iodide uptake assays Primary thyrocytes were grown on 2 cm 2 culture wells in 0.5 ml medium at equal density. Thyroid cell function was assayed by addition of NaI (final concentration 10 À7 mol/l) and 0.05 mCi 125 I (Amersham International, Amersham, UK) per well for 2 h as we have described previously (Eggo et al., 1996) . The cell layer was rapidly washed with HBSS to remove unincorporated iodide and the cells lysed in 1% SDS. Incorporated radioactivity was counted in a gamma counter.
FGF-2-blocking studies PTTG has been shown to induce both the expression and secretion of FGF-2 and previous attempts by ourselves and others have been successful in depleting secreted FGF-2 by the addition of an anti-FGF-2 blocking antibody (Ishikawa et al., 2001; McCabe et al., 2002) . Either azide-free anti-FGF-2 antibody (Santa-Cruz Biotechnology, Santa Cruz, USA) or an equal dose (200 ng/ml culture medium) of rabbit immunoglobulins (Ig, Sigma Aldrich, UK) used as a control, was added immediately following transfection with plasmids containing VO, PTTG or PBF. Primary thyrocytes were then grown for 48 h before ELISA or 125 I assays.
bFGF ELISA Conditioned medium from primary thyrocytes was harvested 48 h following transfection with VO and WT PTTG. The medium was then centrifuged at 12 000 g for 15 min at 41C. FGF-2 concentration was assayed in 200 ml of the supernatant using the bFGF ELISA assay (Quantikine HS Human FGF Basic Immunoassay Kit, R and D Systems Inc., Abingdon, Oxon, UK) as described previously (Ishikawa et al., 2001) . All treatments (VO or PTTG transfection þ either Ig or FGF-2-blocking antibody) were performed in quadruplicate on two different occasions.
Luciferase assays FRTL-5 cells or primary thyrocytes were transfected with a total of 1 mg of DNA per well of a 12-well plate, comprising 0.45 mg promoter construct, 0.05 mg phRL Renilla (Promega, Poole, UK) and 0.5 mg of VO, PTTG or PBF cDNAs. Fortyeight hours post-transfection, cells were washed in PBS, harvested in 250 ml Â 1 passive lysis buffer (Promega), and subjected to one freeze-thaw cycle at À801C. Subsequently, the dual-luciferase reporter assay system (Promega) was used as per the manufacturer's instructions. To compare hNUE activity in the presence and absence of PTTG and PBF, parallel experiments employed a pGL3-SV40 control construct, with specific hNUE activity calculated by subtraction of the mean constitutive SV40 component. Data were expressed as a ratio of Renilla luciferase activity, which was used to control for transfection efficiency.
Statistical analyses
Data were analysed using SigmaStat and SPSS Version 11.5. Student's t-test and the Mann-Whitney U-test were used for comparison between two groups of parametric and nonparametric data respectively. Analysis of variance and Kruskal-Wallis tests were used for between-group comparisons of multiple groups of parametric and non-parametric data respectively. Significance was taken as Po0.05.
